Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Gynecology

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 142 articles:
HTML format



Single Articles


    October 2022
  1. SAUVAGET C, Bazikamwe S, Lucas E, Ndayikengurukiye A, et al
    Evaluation of effectiveness, acceptability and safety of thermal ablation in the treatment of cervical neoplasia in Burundi.
    Int J Cancer. 2022;151:1120-1126.
    PubMed     Abstract available


    September 2022
  2. ADEBAMOWO SN, Befano B, Cheung LC, Rodriguez AC, et al
    Different human papillomavirus types share early natural history transitions in immunocompetent women.
    Int J Cancer. 2022;151:920-929.
    PubMed     Abstract available


    July 2022
  3. BHATT A, Bhandoria G, Kepenekian V, Bakrin N, et al
    Comments on ' Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer - results from the phase III OVHIPEC trial'.
    Int J Cancer. 2022 Jul 20. doi: 10.1002/ijc.34220.
    PubMed    


  4. KOOLE SN, Schouten PC, van Driel WJ, Sonke GS, et al
    Reply to: Comments on "Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer - results from the phase III OVHIPEC trial".
    Int J Cancer. 2022 Jul 20. doi: 10.1002/ijc.34219.
    PubMed    


  5. JOSHI S, Muwonge R, Kulkarni V, Mandolkar M, et al
    Can we increase the cervical cancer screening interval with an HPV test for women living with HIV? Results of a cohort study from Maharashtra, India.
    Int J Cancer. 2022 Jul 19. doi: 10.1002/ijc.34221.
    PubMed     Abstract available


    June 2022
  6. YOON M, Lee HK, Park EY, Kim JH, et al
    Randomized multicenter phase II trial of prophylactic irradiation of para-aortic lymph nodes in advanced cervical cancer according to tumor hypoxia: Korean Radiation Oncology Group (KROG 07-01) study.
    Int J Cancer. 2022 Jun 25. doi: 10.1002/ijc.34190.
    PubMed     Abstract available


  7. HUSBY A, Wohlfahrt J, Melbye M
    Pregnancy duration and ovarian cancer risk: a 50-year nationwide cohort study.
    Int J Cancer. 2022 Jun 24. doi: 10.1002/ijc.34192.
    PubMed     Abstract available


  8. CAO H, Gong Y, Wang Y
    The prognostic impact of myosteatosis on overall survival in gynecological cancer patients: A meta-analysis and trial sequential analysis.
    Int J Cancer. 2022 Jun 20. doi: 10.1002/ijc.34179.
    PubMed     Abstract available


  9. BAANDRUP L, Galanakis M, Hannibal CG, Dehlendorff C, et al
    Long-term survival of non-localized epithelial ovarian cancer among women using menopausal hormone therapy prior to diagnosis - the Extreme study.
    Int J Cancer. 2022 Jun 18. doi: 10.1002/ijc.34171.
    PubMed     Abstract available


  10. ATWAL A, Snowsill T, Dandy MC, Krum T, et al
    The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and meta-analysis.
    Int J Cancer. 2022 Jun 15. doi: 10.1002/ijc.34165.
    PubMed     Abstract available


  11. TODISCO E, Gigli F, Ronchini C, Amato V, et al
    Hematological disorders after salvage PARPi treatment for ovarian cancer: cytogenetic and molecular defects and clinical outcomes.
    Int J Cancer. 2022 Jun 13. doi: 10.1002/ijc.34162.
    PubMed     Abstract available


  12. SA JK, Kim J, Kang S, Kim SW, et al
    Somatic genomic landscape of East Asian epithelial ovarian carcinoma and its clinical implications from prospective clinical sequencing; A Korean Gynecologic Oncology Group study (KGOG 3047).
    Int J Cancer. 2022 Jun 6. doi: 10.1002/ijc.34150.
    PubMed     Abstract available


  13. HAMPL M, Hesselink AT, Meijer CJLM, Denecke A, et al
    Evaluation of FAM19A4/miR124-2 methylation performance in the management of CIN3 diagnosed pregnant women.
    Int J Cancer. 2022 Jun 6. doi: 10.1002/ijc.34153.
    PubMed     Abstract available


  14. DESAI KT, Adepiti CA, Schiffman M, Egemen D, et al
    Redesign of a rapid, low-cost HPV typing assay to support risk-based cervical screening and management.
    Int J Cancer. 2022 Jun 6. doi: 10.1002/ijc.34151.
    PubMed     Abstract available


    May 2022
  15. HARRIS HR, Guertin KA, Camacho TF, Johnson CE, et al
    Racial disparities in epithelial ovarian cancer survival: An examination of contributing factors in the Ovarian Cancer in Women of African Ancestry (OCWAA) consortium.
    Int J Cancer. 2022 May 28. doi: 10.1002/ijc.34141.
    PubMed     Abstract available


  16. KOOLE SN, Schouten PC, Hauke J, Kluin RJC, et al
    Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer - results from the phase III OVHIPEC trial.
    Int J Cancer. 2022 May 18. doi: 10.1002/ijc.34124.
    PubMed     Abstract available


  17. GIORGI ROSSI P, Ronco G, Mancuso P, Carozzi F, et al
    Performance of HPV E6/E7 mRNA Assay as Primary Screening Test. Results from the NTCC2 Trial.
    Int J Cancer. 2022 May 17. doi: 10.1002/ijc.34120.
    PubMed     Abstract available


  18. JAIN S, Nadeem N, Ulfenborg B, Makela M, et al
    Diagnostic potential of nanoparticle aided assays for MUC16 and MUC1 glycovariants in ovarian cancer.
    Int J Cancer. 2022 May 9. doi: 10.1002/ijc.34111.
    PubMed     Abstract available


  19. HURTADO-SALGADO E, Cardenas-Cardenas L, Salmeron J, Luna-Gordillo R, et al
    Comparative performance of the human papillomavirus test and cytology for primary screening for high-grade cervical intraepithelial neoplasia at the population level.
    Int J Cancer. 2022;150:1422-1430.
    PubMed     Abstract available


    April 2022
  20. ADCOCK R, Nedjai B, Lorincz A, Scibior-Bentkowska D, et al
    DNA methylation testing with S5 for triage of high-risk HPV positive women.
    Int J Cancer. 2022 Apr 27. doi: 10.1002/ijc.34050.
    PubMed     Abstract available


  21. GOTTSCHLICH A, Gondara L, Smith LW, Cook D, et al
    HPV-based screening at extended intervals missed fewer cervical precancers than cytology in the HPV FOr CervicAL Cancer (HPV FOCAL) trial.
    Int J Cancer. 2022 Apr 22. doi: 10.1002/ijc.34039.
    PubMed     Abstract available


  22. ZHANG L, Zhao X, Hu S, Chen S, et al
    Triage performance and predictive value of the human gene methylation panel among women positive on self-collected HPV test: results from a prospective cohort study.
    Int J Cancer. 2022 Apr 22. doi: 10.1002/ijc.34041.
    PubMed     Abstract available


  23. ROMANI C, Capoferri D, Reijnen C, Lonardi S, et al
    L1CAM expression as a predictor of platinum response in high-risk endometrial carcinoma.
    Int J Cancer. 2022 Apr 16. doi: 10.1002/ijc.34035.
    PubMed     Abstract available


  24. STANCZUK GA, Currie H, Forson W, Baxter G, et al
    Self-sampling as the principal modality for population based cervical screening: Five-year follow-up of the PaVDaG study.
    Int J Cancer. 2022;150:1350-1356.
    PubMed     Abstract available


  25. SAHASRABUDDHE VV, Castle PE, Schiffman M, Wentzensen N, et al
    Reply to: Comments on 'Meta-analysis of agreement/concordance statistics in studies comparing self- versus clinician-collected samples for HPV testing in cervical cancer screening'.
    Int J Cancer. 2022 Apr 4. doi: 10.1002/ijc.34013.
    PubMed    


  26. RASHID MU, Muhammad N, Naeemi H, Shehzad U, et al
    Chasing the origin of 23 recurrent BRCA1 mutations in Pakistani breast and ovarian cancer patients.
    Int J Cancer. 2022 Apr 4. doi: 10.1002/ijc.34016.
    PubMed     Abstract available


  27. BRENTNALL AR, Rebolj M
    Comments on: "Meta-analysis of agreement/concordance statistics in studies comparing self-versus clinician-collected samples for HPV testing in cervical cancer screening".
    Int J Cancer. 2022 Apr 4. doi: 10.1002/ijc.34014.
    PubMed    


    March 2022
  28. ZHAO Y, Gao YT, Zhang X, Rockwood AL, et al
    Endogenous sex hormones, aromatase activity and lung cancer risk in postmenopausal never-smoking women.
    Int J Cancer. 2022 Mar 26. doi: 10.1002/ijc.34005.
    PubMed     Abstract available


  29. CABASAG CJ, Fagan PJ, Ferlay J, Vignat J, et al
    Ovarian cancer today and tomorrow: a global assessment by world region and Human Development Index using GLOBOCAN 2020.
    Int J Cancer. 2022 Mar 23. doi: 10.1002/ijc.34002.
    PubMed     Abstract available


    February 2022
  30. LUPIA M, Melocchi V, Bizzaro F, Lo Riso P, et al
    Integrated molecular profiling of patient-derived ovarian cancer models identifies clinically relevant signatures and tumor vulnerabilities.
    Int J Cancer. 2022 Feb 26. doi: 10.1002/ijc.33983.
    PubMed     Abstract available


  31. ARBYN M, Castle PE, Schiffman M, Wentzensen N, et al
    Meta-analysis of agreement/concordance statistics in studies comparing self- versus clinician-collected samples for HPV testing in cervical cancer screening.
    Int J Cancer. 2022 Feb 18. doi: 10.1002/ijc.33967.
    PubMed     Abstract available


    January 2022
  32. YAN X, Zhao W, Wei J, Yao Y, et al
    A serum lipidomics study for the identification of specific biomarkers for endometrial polyps to distinguish them from endometrial cancer or hyperplasia.
    Int J Cancer. 2022 Jan 25. doi: 10.1002/ijc.33943.
    PubMed     Abstract available


  33. MAILLIEZ A, Pigny P, Bogart E, Keller L, et al
    Is ovarian recovery after chemotherapy in young patients with early breast cancer influenced by controlled ovarian hyperstimulation for fertility preservation or tumor characteristics? Results of a prospective study in 126 patients.
    Int J Cancer. 2022 Jan 17. doi: 10.1002/ijc.33933.
    PubMed     Abstract available


  34. VAN DER WATT PJ, Okpara MO, Wishart A, Parker MI, et al
    Nuclear transport proteins are secreted by cancer cells and identified as potential novel cancer biomarkers.
    Int J Cancer. 2022;150:347-361.
    PubMed     Abstract available


  35. YAGI A, Ueda Y, Ikeda S, Miyoshi A, et al
    Improved long-term survival of corpus cancer in Japan: A 40-year population-based analysis.
    Int J Cancer. 2022;150:232-242.
    PubMed     Abstract available


    December 2021
  36. PARK B
    Changes in weight and waist circumference during menopausal transition and postmenopausal breast cancer risk.
    Int J Cancer. 2021 Dec 18. doi: 10.1002/ijc.33906.
    PubMed     Abstract available


  37. HERMENS M, van Altena AM, van der Aa M, Bulten J, et al
    Endometrial cancer prognosis in women with endometriosis and adenomyosis. A retrospective nationwide cohort study of 40,840 women.
    Int J Cancer. 2021 Dec 18. doi: 10.1002/ijc.33907.
    PubMed     Abstract available


  38. HORTLUND M, Muhr LSA, Lagheden C, Hjerpe A, et al
    Audit of laboratory sensitivity of human papillomavirus and cytology testing in a cervical screening program.
    Int J Cancer. 2021;149:2083-2090.
    PubMed     Abstract available


  39. REBOLJ M, Mathews CS, Pesola F, Castanon A, et al
    Acceleration of Cervical Cancer Diagnosis with Human Papillomavirus Testing Below Age 30: Observational Study.
    Int J Cancer. 2021 Dec 12. doi: 10.1002/ijc.33900.
    PubMed     Abstract available


  40. PERSSON MS, Yin W, Doring N, Risnes K, et al
    Gestational age and cancer risk up to young adulthood in Swedish population born 1974-2013: a population-based cohort study.
    Int J Cancer. 2021 Dec 2. doi: 10.1002/ijc.33886.
    PubMed     Abstract available


    November 2021
  41. DESAI KT, Befano B, Xue Z, Kelly H, et al
    The development of "Automated Visual Evaluation" for cervical cancer screening: The promise and challenges in adapting deep-learning for clinical testing.
    Int J Cancer. 2021 Nov 20. doi: 10.1002/ijc.33879.
    PubMed     Abstract available


  42. KIM DS, Ahn HS, Kim HJ
    Statin use and incidence and mortality of breast and gynecology cancer: A cohort study using the National Health Insurance claims database.
    Int J Cancer. 2021 Nov 9. doi: 10.1002/ijc.33869.
    PubMed     Abstract available


  43. BERGHUIS AY, Pijnenborg JFA, Boltje TJ, Pijnenborg JMA, et al
    Sialic acids in gynecological cancer development and progression: Impact on diagnosis and treatment.
    Int J Cancer. 2021 Nov 6. doi: 10.1002/ijc.33866.
    PubMed     Abstract available


  44. SPENCER JC, Campos NG, Burger EA, Sy S, et al
    Potential Effectiveness of a Therapeutic HPV Intervention Campaign in Uganda.
    Int J Cancer. 2021 Nov 6. doi: 10.1002/ijc.33867.
    PubMed     Abstract available


    October 2021
  45. ISLAM S, Dutta P, Sahay O, Gopalakrishnan K, et al
    Feedback-regulated transcriptional repression of FBXO31 by c-Myc triggers ovarian cancer tumorigenesis.
    Int J Cancer. 2021 Oct 27. doi: 10.1002/ijc.33854.
    PubMed     Abstract available


  46. RAVEGNINI G, Gorini F, De Crescenzo E, De Leo A, et al
    Can miRNAs be useful biomarkers in improving prognostic stratification in endometrial cancer patients? An update review.
    Int J Cancer. 2021 Oct 27. doi: 10.1002/ijc.33857.
    PubMed     Abstract available


  47. GUSTINUCCI D, Benevolo M, Cesarini E, Mancuso P, et al
    Accuracy of Different Triage Strategies for HPV Positivity in an Italian Screening Population.
    Int J Cancer. 2021 Oct 27. doi: 10.1002/ijc.33858.
    PubMed     Abstract available


  48. HARPER DM, Rozek LS
    Cervical cancer prevention becomes more efficient.
    Int J Cancer. 2021 Oct 19. doi: 10.1002/ijc.33851.
    PubMed    


  49. PEDERSEN K, Portnoy A, Sy S, Hansen BT, et al
    Switching clinic-based cervical cancer screening programs to HPV self-sampling: A cost-effectiveness analysis of vaccinated and unvaccinated Norwegian women.
    Int J Cancer. 2021 Oct 18. doi: 10.1002/ijc.33850.
    PubMed     Abstract available


  50. SKOLD C, Koliadi A, Enblad G, Stalberg K, et al
    Parity is associated with better prognosis in ovarian germ cell tumors, but not in other ovarian cancer subtypes.
    Int J Cancer. 2021 Oct 14. doi: 10.1002/ijc.33844.
    PubMed     Abstract available


  51. IBRAHIM KHALIL A, Mpunga T, Wei F, Baussano I, et al
    Age-specific burden of cervical cancer associated with HIV: a global analysis with a focus on sub-Saharan Africa.
    Int J Cancer. 2021 Oct 9. doi: 10.1002/ijc.33841.
    PubMed     Abstract available


    September 2021
  52. BANILA C, Lorincz AT, Scibior-Bentkowska D, Clifford GM, et al
    Clinical performance of methylation as a biomarker for cervical carcinoma-in-situ and cancer diagnosis: a worldwide study.
    Int J Cancer. 2021 Sep 25. doi: 10.1002/ijc.33815.
    PubMed     Abstract available


  53. VERHOEF L, Bleeker MCG, Polman N, Steenbergen RDM, et al
    Performance of DNA methylation analysis of ASCL1, LHX8, ST6GALNAC5, GHSR, ZIC1 and SST for the triage of HPV-positive women: results from a Dutch primary HPV-based screening cohort.
    Int J Cancer. 2021 Sep 24. doi: 10.1002/ijc.33820.
    PubMed     Abstract available


  54. WRIGHT TC JR, Stoler MH, Ranger-Moore J, Fang Q, et al
    Clinical Validation of p16/Ki-67 Dual-Stained Cytology Triage of HPV-Positive Women - Results from the IMPACT Trial.
    Int J Cancer. 2021 Sep 18. doi: 10.1002/ijc.33812.
    PubMed     Abstract available


  55. HUGEN N, Kanne H, Simmer F, van de Water C, et al
    Umbilical metastases: Real-world data shows abysmal outcome.
    Int J Cancer. 2021;149:1266-1273.
    PubMed     Abstract available


  56. POISEUIL M, Tron L, Woronoff AS, Tretarre B, et al
    How do age and social environment affect the dynamics of death hazard and survival in patients with breast or gynecological cancer in France?
    Int J Cancer. 2021 Sep 14. doi: 10.1002/ijc.33803.
    PubMed     Abstract available


  57. SARINK D, White KK, Loo LWM, Wu AH, et al
    Racial/ethnic differences in postmenopausal breast cancer risk by hormone receptor status: the Multiethnic Cohort Study.
    Int J Cancer. 2021 Sep 6. doi: 10.1002/ijc.33795.
    PubMed     Abstract available


  58. COLE SE, John EM, Hines LM, Phipps AI, et al
    Cumulative menstrual months and breast cancer risk by hormone receptor status and ethnicity: The Breast Cancer Etiology in Minorities (BEM) Study.
    Int J Cancer. 2021 Sep 1. doi: 10.1002/ijc.33791.
    PubMed     Abstract available


  59. IYOSHI S, Yoshihara M, Nakamura K, Sugiyama M, et al
    Pro-tumoral behavior of omental adipocyte-derived fibroblasts in tumor microenvironment at the metastatic site of ovarian cancer.
    Int J Cancer. 2021 Sep 1. doi: 10.1002/ijc.33770.
    PubMed     Abstract available


    August 2021
  60. SALTA S, Maia-Moco L, Estevao-Pereira H, Sequeira JP, et al
    Performance of DNA methylation-based biomarkers in the Cervical Cancer Screening Program of Northern Portugal: a feasibility study.
    Int J Cancer. 2021 Aug 30. doi: 10.1002/ijc.33778.
    PubMed     Abstract available


  61. ZHENG KH, Zhu K, Wactawski-Wende J, Freudenheim JL, et al
    Caffeine Intake from Coffee and Tea and Invasive Breast Cancer Incidence among Postmenopausal Women in the Women's Health Initiative.
    Int J Cancer. 2021 Aug 21. doi: 10.1002/ijc.33771.
    PubMed     Abstract available


  62. WANG T, Jake-Schoffman DE, Townsend MK, Vinci C, et al
    Early life physical activity and risk of ovarian cancer in adulthood.
    Int J Cancer. 2021 Aug 16. doi: 10.1002/ijc.33760.
    PubMed     Abstract available


  63. ZHAO S, Chen L, Zang Y, Liu W, et al
    Endometrial cancer in lynch syndrome.
    Int J Cancer. 2021 Aug 16. doi: 10.1002/ijc.33763.
    PubMed     Abstract available


  64. KEANE A, Ng CW, Simms KT, Nguyen D, et al
    The road to cervical cancer elimination in Malaysia: Evaluation of the impact and cost-effectiveness of HPV screening with self-collection and digital registry support.
    Int J Cancer. 2021 Aug 7. doi: 10.1002/ijc.33759.
    PubMed     Abstract available


    July 2021
  65. COUGHLAN AY, Testa G
    Exploiting epigenetic dependencies in ovarian cancer therapy.
    Int J Cancer. 2021 Jul 2. doi: 10.1002/ijc.33727.
    PubMed     Abstract available


    June 2021
  66. VAN SCHALKWYK C, Moodley J, Welte A, Johnson LF, et al
    Modelling the impact of prevention strategies on cervical cancer incidence in South Africa.
    Int J Cancer. 2021 Jun 24. doi: 10.1002/ijc.33716.
    PubMed     Abstract available


  67. DARELIUS A, Kristjansdottir B, Dahm-Kahler P, Strandell A, et al
    Risk of epithelial ovarian cancer Type I and II after hysterectomy, salpingectomy and tubal ligation - A nationwide case control study.
    Int J Cancer. 2021 Jun 21. doi: 10.1002/ijc.33714.
    PubMed     Abstract available


  68. BUDUKH A, Dikshit R, Chaturvedi P
    Outcome of the randomized control screening trials on Oral, Cervix and Breast Cancer from India and way forward in COVID-19 pandemic situation.
    Int J Cancer. 2021 Jun 21. doi: 10.1002/ijc.33712.
    PubMed    


  69. PAVONE R, Pacquement H, Pasquet M, Sudour-Bonnange H, et al
    Childhood ovarian non-seminomatous germ cell tumors: A Highly Curable Disease With Few Long-Term Treatment-Related Toxicities. Results of the French TGM95 study.
    Int J Cancer. 2021 Jun 19. doi: 10.1002/ijc.33710.
    PubMed     Abstract available


  70. JAYARAJ R, Shaw P, Kumarasamy C, Shetty SS, et al
    Comments on "Cumulative risk of cervical intraepithelial neoplasia for women with normal cytology but positive for human papillomavirus: Systematic review and meta-analysis".
    Int J Cancer. 2021;148:2857-2858.
    PubMed    


  71. MALAGON T, Volesky KD, Franco EL
    Reply to: Comments on cumulative risk of cervical intraepithelial neoplasia for women with normal cytology but positive for human papillomavirus: Systematic review and meta-analysis.
    Int J Cancer. 2021;148:2859-2860.
    PubMed    


    May 2021
  72. DEREJE N, Addissie A, Worku A, Gebremariam A, et al
    Association between waiting time for radiotherapy initiation and disease progression among women with cervical cancer in Addis Ababa, Ethiopia.
    Int J Cancer. 2021 May 17. doi: 10.1002/ijc.33689.
    PubMed     Abstract available


  73. KITAZAWA S, Takaoka Y, Ueda Y, Kitazawa R, et al
    Identification of Calmodulin-Like Protein 5 (CALML5) as tumor-suppressor gene silenced during early stage of carcinogenesis in squamous cell carcinoma of uterine cervix.
    Int J Cancer. 2021 May 17. doi: 10.1002/ijc.33687.
    PubMed     Abstract available


  74. WANG T, Townsend MK, Eliassen AH, Terry KL, et al
    Pre- and post-diagnosis leisure time physical activity and survival following diagnosis with ovarian cancer.
    Int J Cancer. 2021 May 8. doi: 10.1002/ijc.33676.
    PubMed     Abstract available


    April 2021
  75. RAMACHANDRAN D, Wang Y, Schurmann P, Hulse F, et al
    Association of genomic variants at PAX8 and PBX2 with cervical cancer risk.
    Int J Cancer. 2021 Apr 27. doi: 10.1002/ijc.33614.
    PubMed     Abstract available


  76. GREEN LI, Mathews CS, Waller J, Kitchener H, et al
    Attendance at early recall and colposcopy in routine cervical screening with human papillomavirus testing.
    Int J Cancer. 2021;148:1850-1857.
    PubMed     Abstract available


  77. HOPPE-SEYLER K, Herrmann AL, Daschle A, Kuhn BJ, et al
    Effects of Metformin on the virus/host cell crosstalk in HPV-positive cancer cells.
    Int J Cancer. 2021 Apr 12. doi: 10.1002/ijc.33594.
    PubMed    


  78. BORGFELDT C, Soderlund-Strand A, Darlin Flygh L, Forslund O, et al
    HPV73 in cervical cancer and distribution of HPV73 variants in cervical dysplasia.
    Int J Cancer. 2021 Apr 9. doi: 10.1002/ijc.33590.
    PubMed     Abstract available


  79. IVERSEN L, Fielding S, Lidegaard O, Hannaford PC, et al
    Contemporary hormonal contraception and cervical cancer in women of reproductive age.
    Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33585.
    PubMed     Abstract available


  80. PARRA SG, Lopez-Orellana LM, Molina Duque AR, Carns JL, et al
    Reply to: Comments on Cervical cancer prevention in El Salvador: A prospective evaluation of screening and triage strategies incorporating high-resolution microendoscopy to detect cervical precancer.
    Int J Cancer. 2021 Apr 4. doi: 10.1002/ijc.33586.
    PubMed    


  81. PRETORIUS RG, Belinson JL
    COMMENTS ON: CERVICAL CANCER PREVENTION IN EL SALVADOR: A PROSPECTIVE EVALUATION OF SCREENING AND TRIAGE STRATEGIES INCORPORATING HIGH-RESOLUTION MICROENDOSCOPY TO DETECT CERVICAL PRECANCER.
    Int J Cancer. 2021 Apr 4. doi: 10.1002/ijc.33587.
    PubMed    


  82. LI N, Hu Y, Zhang X, Liu Y, et al
    DNA methylation markers as triage test for the early identification of cervical lesions in a Chinese population.
    Int J Cancer. 2021;148:1768-1777.
    PubMed     Abstract available


  83. DIMOU NL, Papadimitriou N, Mariosa D, Johansson M, et al
    Circulating adipokine concentrations and risk of five obesity-related cancers: A Mendelian randomization study.
    Int J Cancer. 2021;148:1625-1636.
    PubMed     Abstract available


  84. CHRISTAKOUDI S, Pagoni P, Ferrari P, Cross AJ, et al
    Weight change in middle adulthood and risk of cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort.
    Int J Cancer. 2021;148:1637-1651.
    PubMed     Abstract available


    March 2021
  85. VINK FJ, Dick S, Heideman DAM, De Strooper LMA, et al
    Classification of high-grade CIN by p16(ink4a) , Ki-67, HPV E4 and FAM19A4/miR124-2 methylation status demonstrates considerable heterogeneity with potential consequences for management.
    Int J Cancer. 2021 Mar 17. doi: 10.1002/ijc.33566.
    PubMed     Abstract available


  86. WATTS EL, Perez-Cornago A, Knuppel A, Tsilidis KK, et al
    Prospective analyses of testosterone and SHBG with risk of 19 types of cancer in men and postmenopausal women in UK Biobank.
    Int J Cancer. 2021 Mar 15. doi: 10.1002/ijc.33555.
    PubMed     Abstract available


  87. ZHAO XL, Liu ZH, Zhao S, Hu SY, et al
    Efficacy of point-of-care thermal ablation among high-risk human papillomavirus positive women in China.
    Int J Cancer. 2021;148:1419-1427.
    PubMed     Abstract available


  88. CHINULA L, Topazian HM, Mapanje C, Varela A, et al
    Uptake and safety of community-based 'screen-and-treat' with thermal ablation preventive therapy for cervical cancer prevention in rural Lilongwe, Malawi.
    Int J Cancer. 2021 Mar 9. doi: 10.1002/ijc.33549.
    PubMed     Abstract available


  89. CROSBIE EJ, Flaum N, Harkness EF, Clayton RD, et al
    Specialist oncological surgery for removal of the ovaries and fallopian tubes in BRCA1 and BRCA2 pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels.
    Int J Cancer. 2021;148:1155-1163.
    PubMed     Abstract available


    February 2021
  90. HALL MT, Smith MA, Simms KT, Barnabas R, et al
    Elimination of cervical cancer in Tanzania: Modelled analysis of elimination in the context of endemic HIV infection and active HIV control.
    Int J Cancer. 2021 Feb 26. doi: 10.1002/ijc.33533.
    PubMed     Abstract available


  91. YANG J, Sasamoto N, Babic A, Vitonis AF, et al
    Intrauterine device use and risk of ovarian cancer: results from the New England Case-Control study and Nurses' Health Studies.
    Int J Cancer. 2021 Feb 26. doi: 10.1002/ijc.33531.
    PubMed     Abstract available


  92. HORTLUND M, van Mol T, Van de Pol F, Bogers JP, et al
    Human Papillomavirus Load and Genotype Analysis Improves the Prediction of Invasive Cervical Cancer.
    Int J Cancer. 2021 Feb 14. doi: 10.1002/ijc.33519.
    PubMed     Abstract available


  93. DONKEN R, van Niekerk D, Hamm J, Spinelli JJ, et al
    Declining Rates of Cervical Intraepithelial Neoplasia in British Columbia, Canada: An Ecological Analysis On The Effects of The School-Based HPV Vaccination Program.
    Int J Cancer. 2021 Feb 14. doi: 10.1002/ijc.33513.
    PubMed    


  94. ARTHUR RS, Dannenberg AJ, Rohan TE
    The association of prediagnostic circulating levels of cardiometabolic markers, testosterone and SHBG with risk of breast cancer among normal weight postmenopausal women in the UK Biobank.
    Int J Cancer. 2021 Feb 10. doi: 10.1002/ijc.33508.
    PubMed     Abstract available


  95. HUANG HJ, Tung HJ, Yang LY, Chao A, et al
    Role of human papillomavirus status after conization for high-grade cervical intraepithelial neoplasia.
    Int J Cancer. 2021;148:665-672.
    PubMed     Abstract available


    January 2021
  96. BETHEA TN, Ochs-Balcom HM, Bandera EV, Beeghly-Fadiel A, et al
    First- and second-degree family history of ovarian and breast cancer in relation to risk of invasive ovarian cancer in African American and White women.
    Int J Cancer. 2021 Jan 31. doi: 10.1002/ijc.33493.
    PubMed     Abstract available


  97. EL-ZEIN M, Gotlieb W, Gilbert L, Hemmings R, et al
    Dual staining for p16/Ki-67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing study.
    Int J Cancer. 2021;148:492-501.
    PubMed     Abstract available


  98. INTURRISI F, Lissenberg-Witte BI, Veldhuijzen NJ, Bogaards JA, et al
    Estimating the direct effect of human papillomavirus vaccination on the lifetime risk of screen-detected cervical precancer.
    Int J Cancer. 2021;148:320-328.
    PubMed     Abstract available


  99. O'BRIEN KM, Tworoger SS, Harris HR, Trabert B, et al
    Genital powder use and risk of uterine cancer: A pooled analysis of prospective studies.
    Int J Cancer. 2021 Jan 12. doi: 10.1002/ijc.33470.
    PubMed     Abstract available


  100. WANG B, Yao J, Ma R, Liu D, et al
    The mutational landscape and prognostic indicators of pseudomyxoma peritonei originating from the ovary.
    Int J Cancer. 2021 Jan 5. doi: 10.1002/ijc.33460.
    PubMed     Abstract available


  101. PREOBRAZHENSKAYA EV, Shleykina AU, Gorustovich OA, Martianov AS, et al
    Frequency and molecular characteristics of PALB2-associated cancers in Russian patients.
    Int J Cancer. 2021;148:203-210.
    PubMed     Abstract available


  102. THUIJS NB, van Beurden M, Bruggink AH, Steenbergen RDM, et al
    Vulvar intraepithelial neoplasia: Incidence and long-term risk of vulvar squamous cell carcinoma.
    Int J Cancer. 2021;148:90-98.
    PubMed     Abstract available


    December 2020
  103. PARRA SG, Lopez-Orellana LM, Molina Duque AR, Carns JL, et al
    Cervical cancer prevention in El Salvador: A prospective evaluation of screening and triage strategies incorporating high-resolution microendoscopy to detect cervical precancer.
    Int J Cancer. 2020 Dec 24. doi: 10.1002/ijc.33454.
    PubMed     Abstract available


  104. CHOI J, Jia G, Wen W, Long J, et al
    Evaluating polygenic risk scores in assessing risk of nine solid and hematologic cancers in European descendants.
    Int J Cancer. 2020;147:3416-3423.
    PubMed     Abstract available


  105. LU W, He F, Lin Z, Liu S, et al
    Dysbiosis of the endometrial microbiota and its association with inflammatory cytokines in endometrial cancer.
    Int J Cancer. 2020 Dec 7. doi: 10.1002/ijc.33428.
    PubMed     Abstract available


    November 2020
  106. LU Z, Zhu M, Marley JL, Bi K, et al
    The combined action of Mo-MDSCs and MAIT cells promotes the progression of cervical cancer.
    Int J Cancer. 2020 Nov 27. doi: 10.1002/ijc.33411.
    PubMed     Abstract available


  107. AN Y, Yang Q
    Tumor-associated macrophage targeted therapeutics in ovarian cancer.
    Int J Cancer. 2020 Nov 24. doi: 10.1002/ijc.33408.
    PubMed     Abstract available


  108. SINGH K, Gillett S, Ireson J, Hills A, et al
    M-EA (methotrexate, etoposide, dactinomycin) and EMA-CO (methotrexate, etoposide, dactinomycin / cyclophosphamide, vincristine) regimens as first line treatment of high-risk Gestational Trophoblastic Neoplasia.
    Int J Cancer. 2020 Nov 19. doi: 10.1002/ijc.33403.
    PubMed     Abstract available


  109. KESSOUS R, Wissing MD, Laskov I, Abitbol J, et al
    Multiple lines of chemotherapy for patients with high-grade ovarian cancer - predictors for response and effect on survival.
    Int J Cancer. 2020 Nov 16. doi: 10.1002/ijc.33395.
    PubMed     Abstract available


  110. ABDULRAHMAN Z, de Miranda NFCC, Hellebrekers BWJ, de Vos van Steenwijk PJ, et al
    A pre-existing coordinated inflammatory microenvironment is associated with complete response of vulvar high-grade squamous intraepithelial lesions to different forms of immunotherapy.
    Int J Cancer. 2020;147:2914-2923.
    PubMed     Abstract available


  111. BRAY F, Laversanne M, Weiderpass E, Arbyn M, et al
    Geographic and temporal variations in the incidence of vulvar and vaginal cancers.
    Int J Cancer. 2020;147:2764-2771.
    PubMed     Abstract available


  112. MALAGON T, Volesky KD, Bouten S, Laprise C, et al
    Cumulative risk of cervical intraepithelial neoplasia for women with normal cytology but positive for human papillomavirus: Systematic review and meta-analysis.
    Int J Cancer. 2020;147:2695-2707.
    PubMed     Abstract available


  113. PINHEIRO M, Gage JC, Clifford GM, Demarco M, et al
    Association of HPV35 with cervical carcinogenesis among women of African ancestry: Evidence of viral-host interaction with implications for disease intervention.
    Int J Cancer. 2020;147:2677-2686.
    PubMed     Abstract available


  114. BIZZARRI N, Anchora LP, Cattani P, De Vincenzo R, et al
    Peritoneal Hpv-Dna Test In Cervical Cancer (Pioneer Study): A Proof Of Concept.
    Int J Cancer. 2020 Nov 5. doi: 10.1002/ijc.33380.
    PubMed     Abstract available


  115. XUE Z, Novetsky AP, Einstein MH, Marcus JZ, et al
    A demonstration of automated visual evaluation of cervical images taken with a smartphone camera.
    Int J Cancer. 2020;147:2416-2423.
    PubMed     Abstract available


    October 2020
  116. REINHOLDT K, Thomsen LT, Munk C, Dehlendorff C, et al
    Incidence of HPV-related anogenital precancer and cancer in women with diabetes - a nationwide registry-based cohort study.
    Int J Cancer. 2020 Oct 31. doi: 10.1002/ijc.33365.
    PubMed     Abstract available


  117. TIAN X, Ge D, Zhang F, Zhang B, et al
    Dynamic analysis of circulating tumor DNA to predict prognosis and monitor therapeutic response in metastatic relapsed cervical cancer.
    Int J Cancer. 2020 Oct 28. doi: 10.1002/ijc.33362.
    PubMed     Abstract available


  118. JORDAN SJ, Na R, Weiderpass E, Adami HO, et al
    Pregnancy Outcomes and Risk of Endometrial Cancer: A Pooled Analysis of Individual Participant Data in the Epidemiology of Endometrial Cancer Consortium.
    Int J Cancer. 2020 Oct 26. doi: 10.1002/ijc.33360.
    PubMed     Abstract available


  119. REZHAKE R, Chen F, Hu SY, Zhao XL, et al
    Triage options to manage high-risk human papillomavirus-positive women: A population-based cross-sectional study from rural China.
    Int J Cancer. 2020;147:2053-2064.
    PubMed     Abstract available


  120. YANG C, Zhang L, Love-Gregory L, Sun L, et al
    Identification of Novel ALK Rearrangements in Gynecologic Clear Cell Carcinoma.
    Int J Cancer. 2020 Oct 9. doi: 10.1002/ijc.33330.
    PubMed     Abstract available


  121. MAJIDI A, Na R, Jordan SJ, De Fazio A, et al
    Statin use and survival following a diagnosis of ovarian cancer: A prospective observational study.
    Int J Cancer. 2020 Oct 9. doi: 10.1002/ijc.33333.
    PubMed     Abstract available


  122. RAMIREZ AT, Sanchez GI, Nedjai B, Agudelo MC, et al
    Effective methylation triage of HPV positive women with abnormal cytology in a middle-income country.
    Int J Cancer. 2020 Oct 2. doi: 10.1002/ijc.33314.
    PubMed     Abstract available


  123. CUZICK J, Adcock R, Carozzi F, Gillio-Tos A, et al
    Combined use of cytology, p16 immunostaining and genotyping for triage of women positive for high-risk human papillomavirus at primary screening.
    Int J Cancer. 2020;147:1864-1873.
    PubMed     Abstract available


    September 2020
  124. BONDE J, Floore A, Ejegod D, Vink FJ, et al
    Methylation markers FAM19A4 and miR124-2 as triage strategy for primary HPV screen positive women; A large European multi-center study.
    Int J Cancer. 2020 Sep 30. doi: 10.1002/ijc.33320.
    PubMed     Abstract available


  125. ONG JS, Derks EM, Eriksson M, An J, et al
    Evaluating the role of alcohol consumption in breast and ovarian cancer susceptibility using population-based cohort studies and two-sample Mendelian randomization analyses.
    Int J Cancer. 2020 Sep 25. doi: 10.1002/ijc.33308.
    PubMed     Abstract available


  126. STALIN J, Traboulsi W, Vivancos-Stalin L, Nollet M, et al
    Therapeutic targeting of soluble CD146/MCAM with the M2J-1 monoclonal antibody prevents metastasis development and procoagulant activity in CD146-positive invasive tumors.
    Int J Cancer. 2020;147:1666-1679.
    PubMed     Abstract available


  127. APOSTOLOU P, Fostira F, Kouroussis C, Kalfakakou D, et al
    BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects.
    Int J Cancer. 2020;147:1334-1342.
    PubMed     Abstract available


  128. EL-ZEIN M, Cheishvili D, Gotlieb W, Gilbert L, et al
    Genome-wide DNA methylation profiling identifies two novel genes in cervical neoplasia.
    Int J Cancer. 2020;147:1264-1274.
    PubMed     Abstract available


    August 2020
  129. LOOPIK DL, Ebisch RM, IntHout J, Melchers WJ, et al
    The relative risk of noncervical high-risk human papillomavirus-related (pre)malignancies after recurrent cervical intraepithelial neoplasia grade 3: A population-based study.
    Int J Cancer. 2020;147:897-900.
    PubMed     Abstract available


  130. WALPOLE E, Dunn N, Youl P, Harden H, et al
    Nonbreast cancer incidence, treatment received and outcomes: Are there differences in breast screening attendees versus nonattendees?
    Int J Cancer. 2020;147:856-865.
    PubMed     Abstract available


    July 2020
  131. BURGER EA, Portnoy A, Campos NG, Sy S, et al
    Choosing the optimal HPV vaccine: The health impact and economic value of the nonavalent and bivalent HPV vaccines in 48 Gavi-eligible countries.
    Int J Cancer. 2020 Jul 24. doi: 10.1002/ijc.33233.
    PubMed     Abstract available


  132. LOUVANTO K, Eriksson T, Gray P, Apter D, et al
    Baseline findings and safety of infrequent vs. frequent screening of human papillomavirus vaccinated women.
    Int J Cancer. 2020;147:440-447.
    PubMed     Abstract available


  133. PONTI A, Basu P, Ritchie D, Anttila A, et al
    Key issues that need to be considered while revising the current annex of the European Council Recommendation (2003) on cancer screening.
    Int J Cancer. 2020;147:9-13.
    PubMed     Abstract available


    June 2020
  134. FARNSWORTH A, Roberts JM, Garland SM, Crescini J, et al
    Detection of high-grade cervical disease among women referred directly to colposcopy following a positive HPV screening test varies with age and cytology findings.
    Int J Cancer. 2020 Jun 2. doi: 10.1002/ijc.33128.
    PubMed     Abstract available


    May 2020
  135. JENKINS D, Molijn A, Kazem S, Pirog EC, et al
    Molecular and pathological basis of HPV-negative cervical adenocarcinoma seen in a global study.
    Int J Cancer. 2020 May 31. doi: 10.1002/ijc.33124.
    PubMed     Abstract available


    February 2020
  136. VENETIANER R, Clarke MA, van der Marel J, Tota J, et al
    Identification of HPV Genotypes Causing Cervical Pre-Cancer using Tissue-Based Genotyping.
    Int J Cancer. 2020 Feb 9. doi: 10.1002/ijc.32919.
    PubMed     Abstract available


    January 2020
  137. TRICKEY A, May MT, Gill MJ, Grabar S, et al
    Cause-specific mortality after diagnosis of cancer among HIV-positive patients: a collaborative analysis of cohort studies.
    Int J Cancer. 2020 Jan 31. doi: 10.1002/ijc.32895.
    PubMed     Abstract available


  138. ZHAO XL, Xu XQ, Duan XZ, Rezhake R, et al
    Comparative performance evaluation of different HPV tests and triaging strategies using self-samples and feasibility assessment of thermal ablation in 'colposcopy and treat' approach: a population-based study in rural China.
    Int J Cancer. 2020 Jan 22. doi: 10.1002/ijc.32881.
    PubMed     Abstract available


  139. CHAN K, Liu SS, Wei N, Ngu SF, et al
    Primary HPV testing with cytology versus cytology alone in cervical screening - a prospective randomized controlled trial (RCT) with two rounds of screening in a Chinese population.
    Int J Cancer. 2020 Jan 10. doi: 10.1002/ijc.32861.
    PubMed     Abstract available


    October 2019
  140. SAND FL, Kjaer SK, Frederiksen K, Dehlendorff C, et al
    Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status.
    Int J Cancer. 2019 Oct 24. doi: 10.1002/ijc.32752.
    PubMed     Abstract available


  141. ZORZI M, Del Mistro A, Giorgi Rossi P, Laurino L, et al
    Risk of CIN2 or more severe lesions after negative HPV-mRNA E6/E7 overexpression assay and after negative HPV-DNA test: concurrent cohorts with a 5-year follow up.
    Int J Cancer. 2019 Oct 3. doi: 10.1002/ijc.32695.
    PubMed     Abstract available


  142. CASTLE PE, Burk RD, Massad LS, Eltoum IE, et al
    Epidemiological Evidence that Common HPV Types May Be Common Because of Their Ability to Evade Immune Surveillance: Results from the Women's Interagency HIV Study.
    Int J Cancer. 2019 Oct 2. doi: 10.1002/ijc.32693.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: